N/A N=40 Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps
Muscle Cramp
Primary: Change in Frequency of Leg Cramps — .99; .53 Cramps per week
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms
Leg Cramp, Nocturnal
Primary: Change in Restless Legs Syndrome Quality of Life Instrument (RLSQoL) Over 4 Weeks — 78.92; 80.75; 77.75; 83.16 units on a scale
Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Phase 4 N=30 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
Muscle Cramp · Cirrhosis
Primary: Frequency of Muscle Cramps as Assessed by Patient Survey — 1.14; 1.23 score on a scale
N/A N=32 Leg Thermotherapy for Intermittent Claudication
Peripheral Artery Disease
Primary: Exercise Tolerance Assessed by Measuring Distance (m) Walked in 6-minutes — 388.75; 414.96; 404.29; 419.73 meters
Phase 4 N=23 Mexiletine for the Treatment of Muscle Cramps in ALS
Muscle Cramps in Amyotrophic Lateral Sclerosis
Primary: Daily Muscle Cramps — 6.1; 4.7; 4.9; 2.5 Cramps per 24 hours
Phase 2 N=86 Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
Nocturia
Primary: Change in Nocturia Episodes — 3.6; 3.3; 3.9; 3.6 average nightly voids — p=0.0017
N/A N=30 Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
Nocturia · Hypertension · Sleep Disturbance
Primary: Change in Mean Sleep Time Systolic Blood Pressure Dip Pre- vs Post-intervention — -0.4; 7.3; 3.9 percentage of daytime mean SBP — p=0.65
N/A N=21 Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
Phase 2 N=35 Comparison of Non-Surgical Treatment Options for Chronic Exertional Compartment Syndrome (CECS)
Chronic Exertional Compartment Syndrome
Primary: University of Wisconsin Running Injury and Recovery Index Score at Baseline — 10.86; 11.86; 12.14; 9.75 cumulative score on a 9-item scale
N/A N=8 Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation
Restless Legs Syndrome · Willis-Ekbom Disease
Primary: Change in International Restless Legs Syndrome Rating Scale (IRLS) — 19.5 score on a scale — p=0.0396
Phase 3 N=301 Treatment of Patients With Nocturia
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
Phase 2 N=12 Intravenous Iron Metabolism in Restless Legs Syndrome
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
N/A N=25 Foot Neuromodulation for Nocturnal Enuresis
Bedwetting
Primary: Decrease in Nocturnal Enuresis — 16 Participants
N/A N=28 A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome
Restless Legs Syndrome
Primary: The International Restless Legs Severity Scale — 17.3; 12.3; 16.9; 21.3 score on a scale
N/A N=133 Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
Restless Legs Syndrome
Primary: Number of Subjects for Which the Clinician Reported "Much Improved" or "Very Much Improved" on the Clinical Global Impressions-Improvement (CGI-I) Scale for TOMAC…
N/A N=15 Spinal Cord Stimulation for Restless Legs Syndrome
Restless Legs Syndrome · Neuropathic Pain
Primary: Percent Change MSNA Burst Frequency From Baseline to 60 Minutes — -29; -24 Percent change MSNA burst frequency
Phase 2 N=6 Botulinum Toxin to Treat Restless Legs Syndrome
Restless Legs Syndrome
Primary: Change in Restless Legs Syndrome Rating Scale — -5.0; -1.0; -2.7; -5.0 RLS Rating Score
N/A N=12 Electrical Stimulation of the Muscle Pumps of the Leg
Haemodynamic Physiology
Primary: Venous Haemodynamic Measurements (Volume Flow Rate) — 119; 158; 158; 144 ml/min — p=<0.05
N/A N=56 Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production
Sleep Fragmentation · Poor Quality Sleep · Nocturia
Primary: Change in Nocturnal Polyuria Index — 41.7; 41.7; 34.5; 37.8 percentage of urine volume — p=0.3
N/A N=45 Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy
HIV · AIDS · Peripheral Neuropathy
Primary: Pain Scores at Week 3 — 50.53; 53.76 units on a scale 0-100 (0= no pain)
Phase 3 N=325 XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
Restless Legs Syndrome
Primary: Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) — -9.8; -13.0 scores on a scale — p=0.0015
N/A N=138 Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Nocturia Associated With Nocturnal Polyuria
Primary: Overall Mean Change From Baseline in Mean Number of Nighttime Voids at Week 12 — -2.01 Number of nocturnal voids
Phase 2 N=11 TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Amyotrophic Lateral Sclerosis · Muscle Cramp
Primary: Visual Analog Scale (MCS-VAS) Score — 2.07; 1.7 score on a scale
Phase 3 N=85 Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
Restless Legs Syndrome
Primary: Wake After Sleep Onset (WASO) — 51.50; 78.42; 78.60 minutes — p=<0.0001
Phase 2 N=10 Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
Restless Legs Syndrome · Augmentation
Primary: Change From Baseline (Predose) in Mean International Restless Legs Syndrome (IRLS) Rating Scale at End of Intervention Period — 20.6; 21.6; 16; 18.8 score on a scale
Phase 3 N=326 Treatment of Patients With Nocturia (Non-PK Study)
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
N/A N=27 Hand & Foot Nocturnal Enuresis TENS Study
Bedwetting
Primary: Change in Number of Nights Wet Per 2 Weeks — 11; 8.78; 8.75; 6.22 # nights wet over 2 weeks
Phase 4 N=81 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
Restless Legs Syndrome
Primary: Change From Baseline in the Number of Elevations of Systolic Blood Pressure (BP) During the Night That Are Associated With Periodic Limb Movements (PLMs) at the End of…
Phase 3 N=306 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
Restless Legs Syndrome
Primary: The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS)…